Brokerages Set Kura Oncology, Inc. (NASDAQ:KURA) Target Price at $25.50

Kura Oncology, Inc. (NASDAQ:KURA) has been assigned an average recommendation of “Moderate Buy” from the twelve research firms that are covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $25.50.

KURA has been the topic of a number of research reports. UBS Group decreased their target price on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. BTIG Research lowered shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. StockNews.com raised shares of Kura Oncology from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Kura Oncology in a report on Thursday, February 27th. Finally, TD Cowen restated a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st.

Insider Activity at Kura Oncology

In related news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11. This represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,729 shares of company stock worth $92,307. Insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KURA. Virtus ETF Advisers LLC boosted its position in Kura Oncology by 71.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock valued at $64,000 after buying an additional 3,061 shares during the period. Harbor Advisors LLC purchased a new position in Kura Oncology in the 4th quarter valued at approximately $87,000. E Fund Management Co. Ltd. purchased a new position in Kura Oncology in the 4th quarter valued at approximately $90,000. Corton Capital Inc. purchased a new position in Kura Oncology in the 4th quarter valued at approximately $99,000. Finally, Optimize Financial Inc purchased a new position in Kura Oncology in the 4th quarter valued at approximately $100,000.

Kura Oncology Trading Up 2.1 %

Shares of Kura Oncology stock opened at $7.29 on Friday. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm’s 50-day moving average price is $7.84 and its 200 day moving average price is $12.75. Kura Oncology has a twelve month low of $6.79 and a twelve month high of $23.48. The firm has a market capitalization of $588.70 million, a PE ratio of -3.09 and a beta of 0.85.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analysts’ expectations of $57.96 million. On average, sell-side analysts predict that Kura Oncology will post -2.44 EPS for the current fiscal year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.